PTC Therapeutics (NASDAQ:PTCT) Posts Quarterly Earnings Results, Beats Expectations By $0.68 EPS

PTC Therapeutics (NASDAQ:PTCT) posted its earnings results on Thursday. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.68, Zacks reports. The business had revenue of $360.52 million for the quarter, compared to analyst estimates of $298.63 million. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The firm’s quarterly revenue was up 101.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.83) EPS.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Record results and raised guidance: Second-quarter total revenue reached $361 million, including $239 million in product revenue, prompting PTC to raise 2026 product revenue guidance to $850 million–$950 million and total revenue guidance to $1.18 billion–$1.28 billion. Management believes the company may reach cash-flow breakeven in 2026.
• Sephience launch momentum remains strong: Global Sephience revenue grew 21% sequentially to approximately $151 million, with 1,647 patients on commercial therapy by quarter-end and prescriptions from all U.S. centers of excellence. Japan is ramping quickly, while early-access programs in Europe and other regions are expected to contribute more meaningfully in late 2026 and 2027.
• Patient retention and demand metrics support management’s long-term outlook for Sephience: prescription renewal rates exceed 90%, discontinuations are approximately 20%, and uptake spans treatment-naive patients, prior-therapy failures, switches, and multiple disease severities. PTC continues to project a global commercial opportunity exceeding $2 billion.
• Pipeline progress: Novartis has begun enrolling the approximately 770-patient phase III INVEST-HD study of votoplam, while PTC and Novartis plan to discuss the 24-month data with the FDA in the second half of 2026, including potential accelerated approval pathways. PTC also expects to start the PROVE FA study of vatiquinone in the third quarter and advance its NLRP3, DHODH, and MSH3 programs.
• Strong liquidity but ongoing DMD pressure: Cash, equivalents, and marketable securities totaled $2.23 billion after refinancing most 2026 convertible notes with 0% notes due 2031, supporting potential business development activity. However, the Duchenne franchise faces generic pressure on Emflaza, while Translarna sales continue in certain markets despite regulatory and licensing challenges in Europe.

PTC Therapeutics Stock Performance

PTCT traded down $7.51 during midday trading on Friday, hitting $68.01. The company had a trading volume of 4,329,705 shares, compared to its average volume of 1,280,434. The company has a market capitalization of $5.64 billion, a PE ratio of -117.26, a P/E/G ratio of 6.58 and a beta of 0.53. PTC Therapeutics has a twelve month low of $43.17 and a twelve month high of $90.87. The firm’s 50-day simple moving average is $77.57 and its 200-day simple moving average is $72.74.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Zacks Research upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Royal Bank Of Canada raised their price objective on shares of PTC Therapeutics from $82.00 to $85.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Cantor Fitzgerald boosted their target price on PTC Therapeutics from $124.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. Finally, TD Cowen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $95.75.

Insider Activity at PTC Therapeutics

In other news, insider Neil Gregory Almstead sold 24,613 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $88.89, for a total transaction of $2,187,849.57. Following the transaction, the insider directly owned 60,299 shares in the company, valued at approximately $5,359,978.11. This represents a 28.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Christine Marie Utter sold 19,686 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $75.56, for a total transaction of $1,487,474.16. Following the completion of the transaction, the chief accounting officer owned 70,199 shares of the company’s stock, valued at $5,304,236.44. This trade represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 198,662 shares of company stock valued at $16,347,994 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On PTC Therapeutics

Large investors have recently made changes to their positions in the company. Oxford Asset Management LLP acquired a new stake in PTC Therapeutics in the second quarter worth about $281,000. Advyzon Investment Management LLC acquired a new position in PTC Therapeutics during the 4th quarter valued at about $269,000. Daiwa Securities Group Inc. boosted its stake in shares of PTC Therapeutics by 1,972.5% in the 2nd quarter. Daiwa Securities Group Inc. now owns 5,285 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 5,030 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of PTC Therapeutics during the 4th quarter worth approximately $245,000. Finally, Summit Global Investments acquired a new stake in shares of PTC Therapeutics during the 4th quarter worth approximately $242,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.